Jamieson is pleased to announce that it has advised the management team of Alcresta Therapeutics, Inc., on its acquisition by Linden Capital Partners.
Alcresta Therapeutics is a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases.
Jamieson Corporate Finance US, LLC is a member of FINRA/SIPC.
